
An additional dose of Johnson & Johnson's Covid-19 vaccine has shown an effectiveness of 94 percent, the company just announced in the published results of a phase III trial.
The vaccine from Johnson & Johnson, which was previously a part of the Danish vaccination program, has demonstrated a single-dose vaccine efficacy of 70 percent.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app